Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment

Pérez-García, Juan Antonio; Morales, Robert E.; Valverde, Claudia; Rodon, J Perez; Suárez, Claudio; Semidey, María Eugenia; García‐Patos, Vicente; Bartralot, R.; Serra, Mercè Mateu; Carles, Joan

doi:10.1093/annonc/mdp601

Cited by 6 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We evaluated the dissemination of disease by PET/CT like a recent study (6). PET/CT can be advised especially in late case and locally advanced disease.…”

Section: Discussionmentioning

confidence: 99%

Metastatic Eccrine Porocarcinoma with Indolent Clinical Course

Demırcı¹,

Demirci²,

Ayva³

et al. 2012

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETEkrin porokarsinoma ekrin ter bezlerinin nadir görülen bir malignitesidir. Standart tedavisi yoktur. Biz burada daha önceden uzun süredir cilt lezyonları olan ileri yaş bir metastatik ekrin porokarsinoma olgusunu sunduk. Özellikle ileri yaş ve asemptomatik hastaların metastatik bile olsa tedavisiz takip edilebileceğini gösterdik. Anahtar Kelimeler: Ekrin porokarsinom; Malignite; Metastaz; Pozitron emisyon tomografi (PET) ABSTRACT Eccrine porocarcinoma is a rare malignancy of eccrine sweat glands. Standart treatment remains unclear. We presented metastatic eccrine porocarcinoma in advanced age that has a long history of a preexisting skin lesion. We have shown that asymptomatic patients in advanced age can be followed-up without treatment even in metastatic disease.

show abstract

“…We evaluated the dissemination of disease by PET/CT like a recent study (6). PET/CT can be advised especially in late case and locally advanced disease.…”

Section: Discussionmentioning

confidence: 99%

Metastatic Eccrine Porocarcinoma with Indolent Clinical Course

Demırcı¹,

Demirci²,

Ayva³

et al. 2012

Acta Oncol Tur.

View full text Add to dashboard Cite

show abstract

“…At present, the recommended treatment of localized porocarcinoma is wide surgical resection and in the cases where lymph node metastasis is present, radical lymph node dissection is added. Although anthracylin-based chemotherapy or combination of 5-fluorouracil (5-FU), taxanes and cisplatin are considered to be the first-line treatment for metastatic or locally-advanced porocarcinoma, this type of tumor is recognized as relatively chemoresistant, and no standard systemic treatment exists (4).…”

Section: Introductionmentioning

confidence: 99%

Expression profiles of mTOR pathway proteins in porocarcinoma: A provisional immunohistochemical study

Ishida

Okabe

2012

Biomedical Reports

View full text Add to dashboard Cite

Porocarcinoma is a rare skin appendage carcinoma, with a poor prognosis. At present, the recommended treatment of localized porocarcinoma is wide surgical resection. Although anthracyclin-based chemotherapy or combination of 5-fluorouracil (5-FU), taxanes and cisplatin are considered to be the first-line treatment for metastatic or locally-advanced porocarcinoma, this type of tumor is recognized as relatively chemoresistant, and no standard systemic treatment has been established yet. Mammalian target of rapamycin (mTOR) is an important protein involved in carcinogenesis. mTOR phosphorylates the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and then phosphorylated 4E-BP1 (p4E-BP1) triggers cell cycle progression, cell proliferation and angiogenesis. Therefore, mTOR is believed to be one of the most promising therapeutic targets in various types of carcinomas. However, the expression profiles of mTOR pathway proteins in porocarcinoma have yet to be elucidated. Therefore, we analyzed the expression of mTOR, 4E-BP1 and p4E-BP1 in five cases of porocarcinoma (four invasive and one case) using immunohistochemical methods. mTOR expression was observed in the invasive porocarcinoma cases, but not in the case. 4E-BP1 was expressed in all five cases. p4E-BP1 expression was observed in 3/4 invasive porocarcinoma cases, but not in the case. This preliminary study clearly demonstrated the overexpression of mTOR and its downstream proteins in most of the included invasive porocarcinoma cases. Therefore, mTOR inhibitors could be considered as potential therapeutic modalities for the treatment of metastatic or locally-advanced porocarcinoma.

show abstract